產品詳情
簡單介紹：
Anti-NMDAR3A抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-NMDAR3A抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-NMDAR3A
Cat. Number:
Anti-NMDAR3A抗體KL-12100R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
NR3A is a subunit of the N-methyl-D-aspartate (NMDA) receptors, which belong to the superfamily of glutamate-regulated ion channels and function in pathological and physiological processes in the central nervous system. NR3A is a multi-pass membrane protein that is expressed in fetal brain and is mediated by glycine. It mayAnti-NMDAR3A抗體 be involved in the development of dendritic spines and in the PPP2CB-NMDAR mediated signaling mechanism. NR3A forms a heteromeric channel composed of a Ω subunit (GRIN1), an e subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third subunit (GRIN3A or GRIN3B). The NR3A protein is enriched in post-synaptic plasma membrane and post-synaptic densities and requires the presence of GRIN1 to be targeted at the plasma membrane. The NR3A subunit displays greater than 90% sequence homology to the corresponding subunit in rat.
Also known as:
Chi-1; Glutamate [NMDA] receptorAnti-NMDAR3A抗體 subunit 3A; GRIN3A; N-methyl-D-aspartate receptor; N-methyl-D-aspartate receptor subtype 3A; NMD3A_HUMAN; NMDAR-L; NMDAR-L1; NMDAR3A; NR3A.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Rabbit, .
●
Immunogen: KLH conjugated Anti-NMDAR3A抗體synthetic peptide derived from human NMDAR3A/NR3A.
●
Predicted Molecular Weight: 123kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-NMDAR3A抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-NMDAR3A抗體
Optimal working dilutions must be determined by the end user.
